The Norways’s Investment management company NBIM has over 5 % ownership of the German pharma company Morphosys. The company announced the changes on Friday.
Morphosys is an innovative biopharma company developing the next generation cancer treatments. It has also accepted the deal with the Swiss pharma company Novartis with 142 % premium to its three months stock price.
The board and the supervisory board of Morphosys have decided to recommend the deal. Also the antritrust regulators have given their clearance, the company announced on Friday.
ComteamPUB+ 